Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors
- 1 September 2018
- journal article
- research article
- Published by Elsevier BV in Pathology - Research and Practice
- Vol. 214 (9), 1370-1375
- https://doi.org/10.1016/j.prp.2018.02.018
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A survey of DICER1 hotspot mutations in ovarian and testicular sex cord-stromal tumorsLaboratory Investigation, 2015
- DICER1 and FOXL2 mutations in ovarian sex cord–stromal tumours: a GINECO Group studyHistopathology, 2015
- DICER1 hotspot mutations in non-epithelial gonadal tumoursBritish Journal of Cancer, 2013
- A clinicopathological analysis of 40 cases of ovarian Sertoli–Leydig cell tumorsGynecologic Oncology, 2012
- Virilizing Leydig-Sertoli Cell Ovarian Tumor Associated with Endometrioid Carcinoma of the Endometrium in a Postmenopausal Patient: Case Report and General ConsiderationsClinical Medicine Insights: Case Reports, 2012
- Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)British Journal of Cancer, 2011
- Clinical Syndromes Associated with Ovarian Neoplasms: A Comprehensive ReviewRadioGraphics, 2010
- Endometrial adenocarcinoma involving both horns of a bicornuate uterusJournal of Cancer Research and Therapeutics, 2010
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Ovarian Sertoli - Leydig cell tumorsThe American Journal of Surgical Pathology, 1985